DexCom, Inc. (DXCM) Stock: Price, Forecast & Analyst Target
DexCom, Inc. (DXCM) — MoonshotScore 93/100 (Exceptional band), calculated Nov 18, 2026. Price $80.19 (-2.82%), as of the Nov 19, 2026 trading session; market cap $29.9B. Expected results Feb 11, 2027.
Educational signal · not a buy or sell recommendation · How to read this
DexCom, Inc. · DXCM · NASDAQ · Healthcare · Medical - Devices
Research dated 2026-09-12 (results through Q2 FY2026; Q3 FY2026 not covered): DexCom sells continuous glucose monitoring systems that connect glucose readings with diabetes treatment decisions, clinician workflows, remote monitoring, and digital health applications. Its case depends on whether expanding adoption can continue lifting revenue and profit while international pressure, operating spending, and a demanding valuation leave less room for execution setbacks.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · DexCom (DXCM)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Elite quality, a strong balance sheet and elite growth, but a full valuation; the market is already moving on it. Business Quality: Elite; Financial Safety: Sound; Valuation: Full; Growth Durability: Compounding; Momentum: Surging.
- quarterly revenue $1.34B (Q3 FY2026, quarter ended Sep 2026)
- EPS beat 6 of the last 8 reports
- expected results Feb 11, 2027
Helping: business quality, balance-sheet strength, durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 94 | Exceptional | |
| 94 | Exceptional | |
| 94 | Exceptional | |
| 94 | Exceptional | |
| 93 | Exceptional | |
| 93 | Exceptional |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $80.19 | |
| Change on the day | -2.82% | |
| 52-week range | $56.72–$92.59 | |
| Market capitalisation | $29.9B | — |
| Price / earnings (trailing) | 31.68 | |
| Shares traded on the day | 4.09M | |
| Beta (volatility vs the S&P 500) | 1.44 |
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for DexCom (DXCM): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 17, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is DexCom (DXCM), and what does it report?
Short answer · as of
DexCom is not simply a medical-device manufacturer shipping isolated hardware. Its portfolio combines continuous glucose monitoring systems with Dexcom Share remote monitoring, developer integrations, and direct commercial relationships with endocrinologists, physicians, and diabetes educators.
Research dated 2026-09-12 (results through Q2 FY2026; Q3 FY2026 not covered).
Reported revenue captures the consolidated economics of that connected monitoring portfolio across domestic and international markets. Annual sales and net income have advanced throughout the reported span, while research spending has remained substantial as DexCom develops and supports its glucose-monitoring platform.
What do the latest results show for DexCom (DXCM)?
Short answer · as of
The most recent reported quarter, Q3 FY2026, carried revenue of $1.34B.
Research dated 2026-09-12 (results through Q2 FY2026; Q3 FY2026 not covered).
The latest period extended the upward revenue trend and produced stronger gross profit, operating income, and net income. Gross profit expanded while research and commercial overhead rose more slowly than sales, allowing a larger share of incremental revenue to reach operating profit.
Revenue and reported earnings again exceeded market expectations, continuing a recent run of favorable revenue comparisons. Operating cash flow remained positive but eased from the preceding period, while management separately warned that international revenue would face a headwind relative to its prior outlook.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2026 | $1.34B | $275M | $0.72 (diluted) |
| Q2 FY2026 | $1.31B | $249M | $0.64 (diluted) |
| Q1 FY2026 | $1.19B | $200M | $0.51 (diluted) |
| Q4 FY2025 | $1.26B | $267M | $0.67 (diluted) |
What are the financial strengths and risks for DexCom (DXCM)?
Short answer
Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-12 (results through Q2 FY2026; Q3 FY2026 not covered).
DexCom combines sustained profitability with positive operating cash flow, liquid resources above total debt, and favorable distress and financial-quality screens. Cash and investments provide meaningful flexibility for research and capital spending, while the trailing margins and returns show that the CGM platform is already economically productive.
The tension is that cash and short-term investments have declined across the reported window despite consistently positive operating cash flow. Continued cash contraction, slower CGM sales, or spending that begins outrunning gross-profit growth would weaken the current financial profile; the valuation premium would amplify the consequence of such deterioration.
What should you watch next at DexCom (DXCM)?
Short answer · as of
The next earnings report is expected on Feb 11, 2027.
Research dated 2026-09-12 (results through Q2 FY2026; Q3 FY2026 not covered).
DexCom’s next release needs to preserve the recent combination of sales growth and operating leverage. Watch whether gross profit continues to outpace research and commercial overhead, whether revenue again clears expectations, and whether management’s anticipated international drag becomes visible in the consolidated result.
Cash conversion deserves equal attention. Operating cash flow has stayed positive, yet the liquid balance has moved lower over the broader window; stabilization would strengthen the profitability signal, while another material decline would demand scrutiny. Longer-range consensus expectations assume continued revenue and earnings expansion, raising the importance of execution against the next scheduled release.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
Checked against the records this page reads, on the dates shown above.
How does DexCom compare with its peers?
Short answer
DexCom's score ranks tied for 1st of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-12 (results through Q2 FY2026; Q3 FY2026 not covered).
DexCom differs from device businesses centered on isolated equipment because its offering connects continuous monitoring, treatment decisions, remote sharing, clinician relationships, and application integrations. That structure makes adoption and continued use of the broader CGM ecosystem more important than a conventional hardware shipment cycle.
The same model carries a distinct burden: DexCom must keep advancing the monitoring platform while sustaining commercial reach and protecting margins. Its sizable research commitment, strong profitability, and international exposure make product execution and geographic performance inseparable parts of the comparison with other medical-device companies.
| Company | Price | Market value | Score |
|---|---|---|---|
| DexCom (DXCM) — this page | $80.19 | $29.9B | 93 |
| $105.23 Nov 18, 2026 | $60.5B | 93 5-pillar Nov 18, 2026 | |
| $320.00 Nov 19, 2026 | $12.6B | 92 5-pillar Nov 18, 2026 | |
| $259.57 Nov 18, 2026 | $25.2B | 87 5-pillar Nov 18, 2026 | |
| $139.98 Nov 18, 2026 | $9.71B | 85 5-pillar Nov 18, 2026 | |
| $30.32 Nov 18, 2026 | $12.7B | 84 5-pillar Nov 18, 2026 | |
| $163.96 Nov 18, 2026 | $11.6B | 83 5-pillar Nov 18, 2026 | |
| $103.32 Nov 18, 2026 | $19.6B | 79 5-pillar Nov 18, 2026 | |
| $29.27 Nov 19, 2026 | $28.6B | 78 5-pillar Nov 18, 2026 | |
| $43.64 Nov 18, 2026 | $63.3B | 77 5-pillar Nov 18, 2026 | |
| $370.17 Nov 18, 2026 | $9.95B | 77 5-pillar Nov 18, 2026 | |
| $370.78 Nov 18, 2026 | $30.1B | 71 5-pillar Nov 18, 2026 | |
| $62.10 Nov 19, 2026 | $9.48B | 59 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $86.00 – $115.00
- Consensus target
- $97.85
- Median target
- $96.00
Consensus record · Captured .
Measured against a quoted price of $80.19 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Nov 8, 2026
- Transactions
- 44
- Identified insiders
- 17
- Purchases
- 0
- Sales
- 23
- Other transactions
- 21
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held DXCM in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| Bridgewater Associates | Founded by Ray Dalio | Q3 2026 | 0.13% | $29.47M | Trimmed −14.8% shares |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about DexCom (DXCM)?
- Global Clinical-Grade Wearables for Pharma and Biotech Market Report 2026 | Capitalize on 21.5% CAGR to $7.48B by 2030 as Abbott, Medtronic, DexCom and Philips Scale AI-Driven RPM
- Dexcom Faces Public Outcry and Legal Challenges Over In-App Data Terms
- Is A Medicare Delay The Biggest Risk For DexCom Stock?
Common Questions About DXCM (Healthcare)
Research dated 2026-09-12 (results through Q2 FY2026; Q3 FY2026 not covered); the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
What does Dexcom Share add to the company’s glucose monitors?
Dexcom Share extends the monitoring system into remote observation, allowing glucose information to reach people beyond the wearer. Alongside developer integrations, it makes DexCom’s offering a connected monitoring platform rather than isolated equipment.
Why does DexCom’s international outlook matter after its latest results?
Recent consolidated results showed rising revenue and profit, but management expects international revenue to face a drag relative to its earlier outlook. That pressure could test whether domestic momentum and operating leverage are strong enough to preserve the broader earnings trend.
Can DexCom fund continued investment in continuous glucose monitoring?
Liquid resources exceed total debt, and operating cash flow has remained positive while DexCom continues funding research and capital expenditures. The caution is that cash and short-term investments have declined across the reported window, so cash conversion matters alongside accounting profit.
What do recent DexCom insider transactions indicate?
Directional insider activity consisted of sales rather than purchases, alongside awards, gifts, and in-kind transactions. The pattern documents net selling but does not establish why individual insiders transacted.
What is the DXCM stock price today?
The last price recorded for DexCom, Inc. (DXCM), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the DXCM price target?
The analyst consensus price target for DexCom, Inc. (DXCM), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 25 figures on this page — 1 from SEC filings and earnings calls, 20 from Financial Modeling Prep (FMP), 3 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources (as of 2026-09-12), by section of the research
ETFs that hold DXCM
Funds in our ETF coverage that list DXCM among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| The Obesity ETF (SLIM) | 13.38% | |
| LGHT ETF | 5.39% | |
| Putnam Sustainable Future ETF (PFUT) | 2.37% | |
| First Eagle Mid Cap Equity ETF (FEMD) | 1.69% |